🇺🇸 Neodolpasse in United States

43 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diarrhoea — 5 reports (11.63%)
  2. Metastases To Bone — 5 reports (11.63%)
  3. Renal Impairment — 5 reports (11.63%)
  4. Blood Cholesterol Increased — 4 reports (9.3%)
  5. Epistaxis — 4 reports (9.3%)
  6. Glomerular Filtration Rate Decreased — 4 reports (9.3%)
  7. Headache — 4 reports (9.3%)
  8. Hepatic Mass — 4 reports (9.3%)
  9. Hepatic Steatosis — 4 reports (9.3%)
  10. Hypertension — 4 reports (9.3%)

Source database →

Neodolpasse in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Neodolpasse approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Neodolpasse in United States?

Medical University of Vienna is the originator. The local marketing authorisation holder may differ — check the official source linked above.